Here's why the Imugene (ASX:IMU) share price is up 6% so far this week

Imugene shares are continuing their impressive run…

| More on:

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imugene Limited (ASX: IMU) share price has jumped out of the starting blocks from the opening of trade this week.

Whereas the S&P/ASX 200 index (ASX: XJO) has fallen 0.12% today, Imugene shares are 5% in the green. They have now climbed 6% in two days.

Let's investigate further.

What's happening with Imugene this week?

The Imugene share price has benefitted from several tailwinds over the last few days.

Firstly, the company's ticker was added to the S&P/ASX 300 index by Standard and Poor's Dow Jones Indices (S&P DJI) on 3 September.

Imugene's inclusion came on the back of index rebalancing that takes place each quarter.

The decision to place a ticker into the index is based on several criteria, such as market capitalisation and liquidity. Obviously, Imugene shares fit the bill in that regard.

In addition, Imugene recently advised it had achieved positive results in its Phase 2 HER-Vaxx clinical trial.

The trial investigated the safety and efficacy profile of the company's immunotherapy candidate HER-Vaxx in a particular type of gastric cancer.

As a result of the positive data, Imugene now "plans two further company sponsored Phase 2 studies and one investigator sponsored study" investigating HER-vaxx's use as an intervention in HER-2 gastric cancer.

Finally, in further news that could be affecting the Imugene share price, the company announced today it had passed all resolutions at its "extraordinary general meeting of shareholders".

The resolutions were originally set out on 6 August. They pertained to shares that were supposed to be issued to Imugene's executive chair, Paul Hopper.

Hopper was due to receive these shares if the company reached a clinical milestone that resulted from Imugene's acquisition of Vaxina Pty Ltd, of which Hopper was the majority shareholder.

Specifically, the milestone was the US Food and Drug Administration (FDA) granting Imugene rights to a phase 1 clinical trial using Vaxina's CF33 oncology technology.

Due to a discrepancy in time zones and other unforeseeable factors, these shares were not transferred to Hopper. As such, the decision was left to shareholders to vote on the same.

Shareholders subsequently voted in favour of the exchange.

Imugene share price snapshot

The Imugene share price has climbed 315% this year to date, and 730% over the past 12 months.

Both of these results have far outpaced the broad index's return of around 25% over the past year.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

The markets lost their steam this Thursday.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why Catapult, Hutchinson, SKS, and West African shares are pushing higher today

These shares are having a strong session despite the market weakness.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

Up 72% in 2025, why is this ASX 200 gold stock racing ahead of the benchmark again today?

Investors are bidding up this high-flying ASX 200 gold stock again on Thursday. But why?

Read more »

Businessman smiles with arms outstretched after receiving good news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a wonderful Wednesday session for investors today.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Gold

3 reasons this ASX 200 gold mining giant could soar higher into 2026

A leading expert forecasts more outperformance from this surging ASX 200 gold stock.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Share Gainers

Why Adriatic Metals, Catapult, Seek, and TechnologyOne shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares returned to positive territory this Tuesday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Breville, Clarity, EOS, and TechnologyOne shares are racing higher today

These shares are having a strong session on Tuesday. But why?

Read more »